PROTAC technology for sensitizing melanoma to immune checkpoint therapy
Open Access
- 3 August 2026
- journal article
- review article
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 45 (1)
Abstract
Melanoma remains one of the most aggressive malignancies, with limited response to immune checkpoint inhibitors (ICIs) due to primary or acquired resistance. Proteolysis-targeting chimeras (PROTACs) have emerged as a novel therapeutic modality that induces selective degradation of target proteins via the ubiquitin–proteasome system, offering distinct advantages over conventional inhibitors. This review summarizes the design principles and molecular mechanisms of PROTACs, and highlights their emerging role in sensitizing melanoma to immunotherapy. Specifically, PROTACs can restore tumor antigen presentation, reprogram the immunosuppressive tumor microenvironment by targeting regulatory T cells, myeloid-derived suppressor cells, and tumor-associated macrophages, and suppress key oncogenic signaling pathways. We also discuss combination strategies with PD-1/PD-L1 and CTLA-4 blockade, as well as current challenges including poor cell permeability, off-target effects, and acquired resistance. Finally, future perspectives on rational design, tissue-specific delivery systems, and clinical translation are addressed.Keywords
Funding Information
- The Research Project of Zhejiang Chinese Medical University (2025RCZXZK58)
This publication has 113 references indexed in Scilit:
- Innovative immunotherapy approaches: harnessing synergy of dual checkpoint blockade in oncologyNaunyn-Schmiedeberg's Archives of Pharmacology, 2026
- Melanoma and its fibroblastic allies: the emerging importance of CAFs in immune suppression, ECM modulation, and therapy resistanceNaunyn-Schmiedeberg's Archives of Pharmacology, 2025
- G‐Quadruplex RNA Based PROTAC Enables Targeted Degradation of RNA Binding Protein FMRP for Tumor ImmunotherapyAngewandte Chemie International Edition, 2024
- A Multifunctional Rocket‐Like Microneedle System with Thrusters for Self‐Promoted Deep Drug Penetration and Combination Treatment in MelanomaAdvanced Functional Materials, 2024
- Acquired and intrinsic resistance to vemurafenib in BRAFV600E‐driven melanoma brain metastasesFEBS Open Bio, 2023
- The new direction of drug development: Degradation of undruggable targets through targeting chimera technologyMedicinal Research Reviews, 2023
- Stimuli‐Responsive PROTACs for Controlled Protein DegradationAngewandte Chemie International Edition, 2023
- Hydrogen Peroxide‐Inducible PROTACs for Targeted Protein Degradation in Cancer CellsChemBioChem, 2023
- Structure‐Based Design of a Macrocyclic PROTACAngewandte Chemie International Edition, 2019
- Myeloid‐derived suppressor cells and tumor: Current knowledge and future perspectivesJournal of Cellular Physiology, 2018